Granted Patent
B2
US 12,577,550 · App. 17/582,958 · Granted Mar 17, 2026
Engineered botulinum neurotoxin
Assignee:
President and Fellows of Harvard College
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein is a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (H C ) having one or more amino acid mutations that modify the binding of the BoNT to the receptor. Specific mutations and combinations of mutations are also disclosed. Isolated modified H C , polypeptides comprising the modified H C , chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.
Claims (35)
1 . A nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), wherein the modified B-Hc comprises two or more amino acid substitutions relative to a reference wild type receptor binding domain of a C. botulinum serotype B, strain 1 as found in SEQ ID NO: 5, wherein the two or more amino acid substitutions are at positions selected from the group consisting of E1191, S1199, W1178, Y1183, and combinations thereof, wherein:
the substitution at position E1191 is E1191A;
the substitution at position S1199 is selected from the group consisting of S1199W, S1199E, and S1199H;
the substitution at position W1178 is selected from the group consisting of W1178Y, W1178Q, W1178A, and W1178S; and
the substitution at position Y1183 is selected from the group consisting of Y1183C, and Y1183P, and
wherein the polypeptide is characterized by enhanced binding to human Syt II as compared to that observed with the reference wild type receptor binding domain.
2 . The nucleic acid of claim 1 , wherein the polypeptide that it encodes comprises:
i) the modified B-Hc possesses 95% or more amino acid sequence identity to the reference wild type receptor binding domain;
ii) the modified B-Hc corresponds to residues 1078-1291 of SEQ ID NO: 5 or residues 859-1291 of SEQ ID NO: 5;
iii) the modified B-H c is of strain 1; or
iv) a combination thereof.
3 . The nucleic acid of claim 1 , wherein the polypeptide that it encodes is a botulinum neurotoxin (BoNT) polypeptide comprising:
a) a protease domain;
b) a protease cleavage site;
c) a translocation domain; and
d) the modified B-Hc.
4 . The nucleic acid of claim 3 , wherein the protease domain, translocation domain, and protease cleavage site are from serotype selected from the group consisting of A, B, C, D, E, F, G, and combinations thereof.
5 . The nucleic acid claim 4 , wherein the protease domain, translocation domain, and protease cleavage site are from serotype B, strain 1 or from serotype A, strain 1.
6 . The nucleic acid of claim 1 , wherein the modified B-Hc comprises two substitution mutations substitutions.
7 . The nucleic acid of claim 6 , wherein that the modified B-Hc comprises two substitutions that correspond to:
E1191M and S1199E;
E1191M and S1199H;
E1191M and W1178Y;
E1191M and W1178A;
E1191M and W1178S;
E1191M and Y1183C; or
E1191M and Y1183P.
8 . The nucleic acid of claim 1 , wherein the modified B-Hc comprises two or more substitutions, wherein one of the substitutions is selected from the group consisting of E1191C, E1191V, and E1191Y.
9 . The nucleic acid of claim 1 , wherein the modified B-Hc comprises three substitutions.
10 . The nucleic acid of claim 9 , wherein the three substitutions are at positions that correspond to:
E1191, Y1183 and S1199; or
E1191, S1199 and W1178.
11 . The nucleic acid of claim 9 , wherein the three substitutions are E1191M, S1199W and W1178Q.
12 . A nucleic acid vector comprising the nucleic acid of claim 1 .
13 . A cell comprising the nucleic acid of claim 1 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 25, 2022
From: DONG, MIN; PENG, LISHENG; TAO, LIANG
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 059698/0396 →
Continuity (3)
Division
15561355
Provisional Application
62138818
· Mar 26, 2015
References Cited (197)
US 4518584A
· Mark et al.
· 1985
[cited by applicant]
US 4737462A
· Mark et al.
· 1988
[cited by applicant]
US 5053005A
· Borodic et al.
· 1991
[cited by applicant]
US 5714468A
· Binder
· 1998
[cited by applicant]
US 5721215A
· Aoki et al.
· 1998
[cited by applicant]
US 5766605A
· Sanders et al.
· 1998
[cited by applicant]
US 5989545A
· Foster et al.
· 1999
[cited by applicant]
US 6113915A
· Aoki et al.
· 2000
[cited by applicant]
US 6967088B1
· Williams et al.
· 2005
[cited by applicant]
US 7189541B2
· Donovan
· 2007
[cited by applicant]
US 7514088B2
· Steward et al.
· 2009
[cited by applicant]
US 7645570B2
· Fernandez-Salas et al.
· 2010
[cited by applicant]
US 7985554B2
· Chapman et al.
· 2011
[cited by applicant]
US 8052979B2
· Steward et al.
· 2011
[cited by applicant]
US 8445650B2
· Simpson et al.
· 2013
[cited by applicant]
US 8476024B2
· Mahrhold et al.
· 2013
[cited by applicant]
US 8481040B2
· Rummel et al.
· 2013
[cited by applicant]
US 8586081B2
· Singh et al.
· 2013
[cited by applicant]
US 8841111B2
· Steward et al.
· 2014
[cited by applicant]
US 9598685B2
· Dong
· 2017
[cited by examiner]
US 20040013687A1
· Simpson et al.
· 2004
[cited by applicant]
US 20080032931A1
· Steward et al.
· 2008
[cited by applicant]
US 20220033447A1
· Dong et al.
· 2022
[cited by applicant]
CA 2874587A1
· 2013
[cited by applicant]
CN 101184770A
· 2008
[cited by applicant]
CN 101903035A
· 2010
[cited by applicant]
CN 101918021A
· 2010
[cited by applicant]
CN 102131823A
· 2011
[cited by applicant]
CN 102481351A
· 2012
[cited by applicant]
CN 104736166A
· 2015
[cited by applicant]
JP 2008538902A
· 2008
[cited by applicant]
KR 1020080014754A
· 2008
[cited by applicant]
WO WO9532738A1
· 1995
[cited by applicant]
WO WO9533850A1
· 1995
[cited by applicant]
WO WO9633273A1
· 1996
[cited by applicant]
WO WO9807864A1
· 1998
[cited by applicant]
WO WO1998008540A1
· 1998
[cited by applicant]
WO WO9917806A1
· 1999
[cited by applicant]
WO WO2006001676A1
· 2006
[cited by applicant]
WO WO2006114308A3
· 2006
[cited by applicant]
WO WO2007144493A2
· 2007
[cited by applicant]
WO WO2008059126A1
· 2008
[cited by applicant]
WO WO2008090287A2
· 2008
[cited by applicant]
WO WO2009014854A1
· 2009
[cited by applicant]
WO WO2009015840A2
· 2009
[cited by applicant]
WO WO2009038770A2
· 2009
[cited by applicant]
WO WO2009055350A1
· 2009
[cited by applicant]
WO WO2009055351A1
· 2009
[cited by applicant]
WO WO2009130600A2
· 2009
[cited by applicant]
WO WO2013180799A1
· 2013
[cited by applicant]
WO WO2013180799A9
· 2014
[cited by examiner]
WO WO2016154534A1
· 2016
[cited by applicant]
WO WO2017214447A1
· 2017
[cited by applicant]
WO WO2018039506A1
· 2018
[cited by applicant]
Puigbo P, Guzman E, Romeu A, Garcia-Vallve S. Optimizer: a web server for optimizing the codon usage of DNA sequences. Nucleic Acids Res. Jul. 2007;35(Web Server issue):W126-31. doi: 10.1093/nar/gkm219. Epub Apr. 16, 20…
[cited by examiner]
Aoki, K. Roger, Botulinum toxin: A Successful Therapeutic Protein, Curr Med Chem, 11: 3085-3092 (2004).
[cited by applicant]
Arnau, J. et al., Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 48(1):1-13 (2006).
[cited by applicant]
Arnon et al., Botulinum Toxin as a Biological Weapon: Medical and Public Health Management, Jama, 285: 1059-1070 (2001).
[cited by applicant]
Atassi et al., Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action, Toxicon, 54(5): 600-613 (2009).
[cited by applicant]
Atassi et al., Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B …
[cited by applicant]
Atassi et al., Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment, Mol Immunol, 45(15): 3878-3888 (2008).
[cited by applicant]
Bauer, C. et al., A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis, Gene, 37(1-3):73-81 (1985).
[cited by applicant]
Benoit, R. et al., Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A, Nature, 505(7481):108-11 (2014).
[cited by applicant]
Berntsson, R. et al., Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II, Structure, 21(9):1602-11 (2013).
[cited by applicant]
Berntsson, R. et al., Structure of dual receptor binding to botulinum neurotoxin B, Nature Communications, 4 (2013).
[cited by applicant]
Berry, M.J. et al., Substitution of cystein for selenocysteine in type I iodothyronine deiodinase reduces the catalytic efficiency of the protein but enhances its translation, Endocrinology, 131(4):1848-1852 (1992).
[cited by applicant]
Binz, T., et al., Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering, Toxins (Basel), 2(4):665-82 (2010).
[cited by applicant]
Blasi, J. et al., Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25, Nature, 365(6442):160-3 (1993).
[cited by applicant]
Bonventre P. and Kempe, L., Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis, and toxin production, Appl Microbiol., 7:374-7…
[cited by applicant]
Bonventre, P. and Kempe, L., Physiology of toxin production by Clostridium botulinum types A and B. IV. Activation of the toxin, J. Bacteriol, 79(1):24-32 (1960).
[cited by applicant]
Brin et al., Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia, Neurology, 53: 1431-1438 (1999).
[cited by applicant]
Brodsky, M. et al., Diffusion of botulinum toxins, Tremor Other Hyperkinet Mov (NY), 7 pages (2012).
[cited by applicant]
Chai et al., Structural basis of cell surface receptor recognition by botulinum neurotoxin B, Nature, 444(7122):1096-1100 (2006).
[cited by applicant]
Chapman et al., Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical Dystonia, Clin Ther, 29: 1325-1337 (2007).
[cited by applicant]
Chen, S. and Barbieri, J., Engineering botulinum neurotoxin to extend therapeutic intervention, Proc Natl Acad Sci USA, 106(23):9180-4 (2009).
[cited by applicant]
Chen, X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 65(10):1357-1369 (2013).
[cited by applicant]
Comella, C. et al., Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia, Neurology, 65(9):1423-9 (2005).
[cited by applicant]
Cote et al., Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases, J Am Acad Dermatol, 53: 407-415 (2005).
[cited by applicant]
Craxton, A manual collection of Syt, Esyt, Rph3a, Rph3al, Doc2, and Dblc2 genes from 46 metazoan genomes—an open access resource for neuroscience and evolutionary biology, BMC Genomics, 11(37): 1-21 (2010).
[cited by applicant]
Dasgupta, B. and Boroff, D., Chromatographic isolation of hemagglutinin-free neurotoxin from crystalline toxin of Clostridium botulinum type A, Biochim Biophys Acta., 147(3):603-5 (1967).
[cited by applicant]
DATABASE Geneseq [Online], Modified Clostridial toxin construct BoNT/B-HA-17 beta, retrieved from EBI accession No. GSP:AZY12935, Database accession No. AZY12935 sequence, 2 pages (2012).
[cited by applicant]
DATABASE UniProt [Online], Neurotoxin B8, retrieved from EBI accession No. UNIPROT:M9VUL2, Database accession No. M9VUL2 sequence, 2 pages (2013).
[cited by applicant]
Dekleva, M.L. et al., Nicking of single chain Clostridium botulinum type A neurotoxin by an endogenous protease, Biochem Biophys Res Commun, 162(2):767-72 (1989).
[cited by applicant]
Dolimbek et al., Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin, Mol Immunol, 45: 910-924 (2008).
[cited by applicant]
Dolly, J. et al., Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics, Curr Opin Pharmacol., 9(3):326-35 (2009).
[cited by applicant]
Dong et al. Glycosylated SV2A and SV2B Mediate the Entry of Botulinum neurotoxin E into neurons, Mol Biol Cell, 19: 5226-5237 (2008).
[cited by applicant]
Dong et al., Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons, J Cell Biol, 179(7): 1511-1522 (2007).
[cited by applicant]
Dong et al., SV2 is the Protein Receptor for Botulinum Neurotoxin A, Science, 312(5773):592-596 (2006) .
[cited by applicant]
Dong et al., Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells, J Cell Biol, 162(7): 1293-1303 (2003).
[cited by applicant]
Duff J. et al., Studies on immunity to toxins of Clostridium botulinum. I. A simplified procedure for isolation of type A toxin, J Bacteriol., 73(1):42-7 (1957).
[cited by applicant]
Duff, J. et al., Studies on immunity to toxins of Clostridium botulinum. II. Production and purification of type B toxin for toxoid, J Bacteriol., 73(5):597-601 (1957).
[cited by applicant]
Finzi, E. and Rosenthal, N., Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial, J Psychiatr Res., 52:1-6 (2014).
[cited by applicant]
Frankel, A.E., et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 13(8):575-581 (2000).
[cited by applicant]
Fu et al., Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype F, Biochemistry, 48(24): 5631-5641 (2009).
[cited by applicant]
Gasser, B. et al., Antibody production with yeasts to filamentous fungi: on the road to large scale?, Biotechnology Letters, 29(2):201-212 (2007).
[cited by applicant]
Guo, J. et al., Engineering Clostridia Neurotoxins with elevated catalytic activity, Toxicon, 74:158-66 (2013).
[cited by applicant]
Hexsel, C. et al., Botulinum toxin type A for aging face and aesthetic uses, Dermatol Ther., 24(1):54-61 (2011).
[cited by applicant]
Hill et al., Genetic diversity among Botulinum Neurotoxin-producing clostridial strains, J Bacteriol, 189(3): 818-832 (2007).
[cited by applicant]
Humeau et al., How botulinum and tetanus neurotoxins block neurotransmitter release, Biochimie, 82(5):427-446 (2000).
[cited by applicant]
Ihara et al., Sequence of the gene for Clostridium botulinum type B neurotoxin associated with infant botulism, expression of the C-terminal half of heavy chain and its binding activity, Biochim Biophys Acta, 1625: 19-2…
[cited by applicant]
International Search Report for PCT/US2016/024211 (Engineered Botulinum Neurotoxin, filed Mar. 25, 2016), issued by ISA/EPO, 8 pages (Sep. 9, 2016).
[cited by applicant]
International Search Report for PCT/US2013/030737 (Engineered Botulinum Neurotoxin, filed Mar. 13, 2013), issued by ISA/EP, 6 pages (Oct. 11, 2013).
[cited by applicant]
International Search Report for PCT/US2017/048508 (Engineered Botulinum Neurotoxin, filed Aug. 24, 2017), issued by ISA/EP, 7 pages (Oct. 24, 2017).
[cited by applicant]
Jackson, J. et al., Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis, JAMA, 307(16):1736-45 (2012).
[cited by applicant]
Jahn, E.M., et al., How to systematically evaluate immunogenicity of therapeutic proteins-regulatory considerations, New biotechnology, 25(5):280-286 (2009).
[cited by applicant]
Jahn, R. and Scheller, R., SNAREs—engines for membrane fusion, Nat Rev Mol Cell Biol., 7(9):631-43 (2006).
[cited by applicant]
Jankovic, J. and Brin, M., Therapeutic uses of botulinum toxin, N Engl J Med., 324(17):1186-94 (1991).
[cited by applicant]
Jiang, Y. et al., Current and potential urological applications of botulinum toxin A, Nat Rev Urol., 12(9):519-33 (2015).
[cited by applicant]
Jin et al., Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity, Nature, 444(7122):1092-1095 (2006).
[cited by applicant]
Jin, R. et al., Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity, Nature, 444(21):1092-1095 (2006).
[cited by applicant]
Johnson, Eric A., Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins, Annu Rev Microbiol, 53: 551-575 (1999).
[cited by applicant]
Karimova, G. et al., A bacterial two-hybrid system based on a reconstituted signal transduction pathway, Proc Natl Acad Sci USA, 95(10):5752-6 (1998).
[cited by applicant]
Kohda, T. et al., Differential contribution of the residues in C-terminal half of the heavy chain of botulinum neurotoxin type B to its binding to the ganglioside GT1b and the synaptotagmin 2/GT1b complex, Microbial Pat…
[cited by applicant]
Kozaki et al., Characterization of Clostridium botulinum Type B Neurotoxin Associated with Infant Botulism in Japan, Infect Immun, 66(10): 4811-4816 (1998).
[cited by applicant]
Lacy, D. et al., Crystal structure of botulinum neurotoxin type A and implications for toxicity, Nat Struct Biol., 5(10):898-902 (1998).
[cited by applicant]
Lalli et al., Functional characterisation of tetanus and botulinum neurotoxins binding domains, J Cell Sci, 112: 2715-2724 (1999).
[cited by applicant]
Lalli et al., The Journey of tetanus and botulinum neurotoxins in neurons, Trends Microbiol, 11 (9): 431-437 (2003).
[cited by applicant]
Lange et al., Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?, Clin Neuropharmacol, 32: 213-218 (2009).
[cited by applicant]
Lee, K., et al., Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex, Science, 344(6190):1405-10 (2014).
[cited by applicant]
Li, X. et al., Clostridium butyricum-Guardian of intestinal health, Fudan University Press, pp. 347-348 (2008) NON-ENGLISH.
[cited by applicant]
Lietzow, M. et al., Composition and Molecular Size of Clostridium botulinum Type A Toxin-Hemagglutinin Complex, Protein J., 28:250-251 (2009).
[cited by applicant]
Lim, E. et al., Botulinum toxin: A novel therapeutic option for bronchial asthma?, Medical Hypotheses, 66:915-919 (2006).
[cited by applicant]
Maeda, Y. et al., Engineering of functional chimeric protein G-Vargula Luciferase, Analytical biochemistry, 249(2):147-152 (1997).
[cited by applicant]
Mahrold et al., The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves, FEBS Lett, 580: 2011-2014 (2006).
[cited by applicant]
Malizio, C. et al., Purification of Clostridium botulinum type A neurotoxin, Methods Mol Biol., 145:27-39 (2000).
[cited by applicant]
Masuyer, G. et al., Engineered botulinum neurotoxins as new therapeutics, Annu Rev Pharmacol Toxicol., 54:27-51 (2014).
[cited by applicant]
Montal, M., Botulinum neurotoxin: a marvel of protein design, Annu Rev Biochem, 79:591-617 (2010).
[cited by applicant]
Montecucco, C. and Molgo, J., Botulinal neurotoxins: revival of an old killer, Curr Opin Pharmacol, 5: 274-279 (2005).
[cited by applicant]
Montecucco, How do tetanus and botulinum toxins bind to neuronal membranes?, TIBS, 11: 314-317 (1986).
[cited by applicant]
Moriishi et al., Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms, Biochim Biophys Acta, 1307: 123-126 (1996).
[cited by applicant]
Muller, S. et al., Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial, Arthritis & Rheumatism, Official Journal of the American College of Rheumatolo…
[cited by applicant]
Munchau, A. and Bhatia, K., Regular Review: Uses of botulinum toxin injection in medicine today, British Medical Journal, 320 (77228):161-165 (2000).
[cited by applicant]
Naumann, M. et al., Botulinum Toxin in Treatment of Neurological Disorders of the Autonomic Nervous System, Arch Neurol., 56:914-916 (1999).
[cited by applicant]
Nishiki et al., Identification of Protein Receptor for Clostridium botulinum Type B Neurotoxin in Rat Brain Synaptosomes, J Biol Chem, 269(14): 10498-10503 (1994).
[cited by applicant]
Nishiki et al., The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a, FEBS Lett 378: 253-257 (1996).
[cited by applicant]
Orlando, M., Modification of proteins and low molecular weight substances with hydroxyethyl starch (HES), Inauguraldissertation, Giesen, p. 166, c. 15 (2003).
[cited by applicant]
Pang et al., Synaptotagmin-2 Is Essential for Survival and Contributes to Ca2+ Triggering of Neurotransmitter Release in Central and Neuromuscular Synapses, J Neurosci, 26(52): 13493-13504 (2006).
[cited by applicant]
Pappert et al., Botulinum Toxin Type B vs. Type A in Toxin-Naive patients with Cervical Dystonia: Randomized, Double-Blind, Noninferiority Trial, Mov Disord, 23(4): 510-517 (2008).
[cited by applicant]
Peng et al., Botulinum Neurotoxin D Uses Synaptic Vesicle Protein SV2 and Gangliosides as Receptors, PLoS Pathog, 7: e1002008 (2011).
[cited by applicant]
Peng et al., Botulinum neurotoxin D-C uses synaptotagmin I/II as receptors and human synaptotagmin II is not an effective receptor for type B, D-C, and G toxins, J Cell Sci, 125(13):3233-3242 (2012).
[cited by applicant]
Peng, L. et al., Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins, PLoS Pathog, 10(7):e1004177 (2014).
[cited by applicant]
Pickett, A. and Perrow, K., Composition and molecular size of Clostridium botulinum Type A toxin-hemagglutinin complex, Protein J., 28(5):248-9 (2009).
[cited by applicant]
Pickett, A., Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology. In Clinical Applications of Botulinum Neurotoxin, Current Topics in Neurotoxicity, Springer New York, pp. 7-49 (2014).
[cited by applicant]
Pirazzini, M et al., Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain, FEBS Lett, 587(23):3831-6 (2013).
[cited by applicant]
Rossetto, O. et al., Botulinum neurotoxins: genetic, structural and mechanistic insights, Nat Rev Microbiol., 12(8):535-49 (2014).
[cited by applicant]
Rummel et al., Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation—dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor, J …
[cited by applicant]
Rummel et al., Exchange of the HCC domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin, FEBS J, 278: 4506-4515 (2011).
[cited by applicant]
Rummel et al., Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept, PNAS, 104(1): 359-364 (2007).
[cited by applicant]
Rummel, A. et al., Synaptotagmins I and II Act as Nerve Cell Receptors for Botulinum Neurotoxin G, The Journal of Biological Chemistry, 279(29): 30865-30870 (2004).
[cited by applicant]
Rummel, A. et al., The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction, Mol Microbiol, 51: 631-643 (2004).
[cited by applicant]
Schantz, E. and Johnson, E., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiol Rev., 56(1):80-99 (1992).
[cited by applicant]
Schiavo et al., Neurotoxins affecting neuroexocytosis, Physiol Rev, 80: 717-766 (2000).
[cited by applicant]
Schiavo, G. et al, Botulinum neurotoxin type B, UnitProtKB—P10844 (BXB_CLOBO), 7 pages (2007).
[cited by applicant]
Sikorra, S. et al., Identification and Characterization of Botulinum Neurotoxin A Substrate Binding Pockets and Their Re-Engineering for Human SNAP-23, J Mol Biol., 428(2Pt A):372-384 (2016).
[cited by applicant]
Snipe, P. and Sommer, H., Studies on botulinus toxin 3. Acid precipitation of botulinus toxin, The Journal of infectious diseases, 43(2):152-160 (1928).
[cited by applicant]
Stanker, L. et al., A Monoclonal Antibody Based Capture ELISA for Botulinum Neutotoxin Serotype B: Toxin Detection in Food, Toxins, 5:2212-2226 (2013).
[cited by applicant]
Strotmeier, J. et al., Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity, FEBS Lett, 586(4):310-3 (2012).
[cited by applicant]
Südhof, T. and Rothman, J., Membrane fusion: grappling with SNARE and SM proteins, Science, 323(5913):474-7 (2009).
[cited by applicant]
Sutton, R. et al., Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution, Nature, 395(6700):347-53 (1998).
[cited by applicant]
Tao, L. and Biswas, I., ClpL is required for folding of CtsR in
[cited by applicant]
Truong, D. and Jost, W., Botulinum toxin: clinical use, Parkinsonism Relat Disord., 12(6):331-55 (2006).
[cited by applicant]
Tse, C. et al., Preparation and characterisation of homogeneous neurotoxin type A from Clostridium botulinum. Its inhibitory action on neuronal release of acetylcholine in the absence and presence of beta-bungarotoxin, …
[cited by applicant]
Turton et al., Botulinum and Tetanus Neurotoxins: structure, function and therapeutic utility, Trends Biochem. Sci., 27(11 ): 552-558 (2002).
[cited by applicant]
Van Baar et al., Characterisation of botulinum toxins type A and B, by matrix-assisted laser desorption ionisation and electrospray mass spectrometry, Journal of Chromatography A, 970(1-2): 95-115 (2002).
[cited by applicant]
Visco, A. et al., Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence., N Engl J Med., 367(19):1803-13 (2012).
[cited by applicant]
Walder, R. and Walder, J., Oligodeoxynucleotide-directed mutagenesis using the yeast transformation system, Gene, 42(2):133-9 (1986).
[cited by applicant]
Wang et al., Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B, Biochem J, 444: 59-67 (2012).
[cited by applicant]
Written Opinion for PCT/US2016/024211 (Engineered Botulinum Neurotoxin, filed Mar. 25, 2016), issued by ISA/EPO, 8 pages (Sep. 9, 2016).
[cited by applicant]
Written Opinion for PCT/US2013/030737 (Engineered Botulinum Neurotoxin, filed Mar. 13, 2013), issued by ISA/EP, 8 pages (Oct. 11, 2013).
[cited by applicant]
Written Opinion for PCT/US2017/048508 (Engineered Botulinum Neurotoxin, filed Aug. 24, 2017), issued by ISA/EP, 13 pages (Oct. 24, 2017).
[cited by applicant]
Yamasaki, S. et al., Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin, J Biol Chem, 269(17):12764-72 (1994).
[cited by applicant]
Fischer, A., Synchronized Chaperone Function of Botulinum Neurotoxin Domains Mediates Light Chain Translocation into Neurons, Botulinum Neurotoxins, 364:115-137 (2012).
[cited by applicant]
You, Z, et al., Advances in research on vaccines and antibodies for defending against botulism, Military Medical Sciences, 7:550-554. (2013).
[cited by applicant]
Wenwen, X, and Jing-Lin, W., Research progress of Clostridial neurotoxins, Chinese Bulletin of Life Sciences, 28(1); 11 pages (2016) English Abstract.
[cited by applicant]